Cardiomyopathy: An overview

American Family Physician

Volumn 79, Issue 9, 2009, Pages 778-784

  Wexler, Randy ^a   Elton, Terry ^a   Pleister, Adam ^a   Feldman, David ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOPROLOL TARTRATE; SOTALOL; SPIRONOLACTONE;

ALCOHOL CONSUMPTION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; COUGHING; DEFIBRILLATOR; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; FATIGUE; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; LIFESTYLE MODIFICATION; PAROXYSMAL DYSPNEA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 67649373403     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816. (Pubitemid 43958474)
2. Buja G, Estes NA III, Wichter T, Corrado D, Marcus F, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: risk stratification and therapy. Prog Cardiovasc Dis. 2008;50(4):282-293. (Pubitemid 350296215)
3. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circulation. 2004;110(14):1879-1884. (Pubitemid 39331895)
4. Rivenes SM, et al. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation. 2000;102(8):876-882. (Pubitemid 30671504)
5. Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation. 2003;108(21):2596-2603. (Pubitemid 37466796)
6. Jones RH, Velazquez EJ, Michler RE, et al., for the STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. In press. http://content.nejm.org/cgi/content/ full/NEJMoa0900559. Published March 29, 2009. Accessed April 10, 2009.
7. Rose EA, Gelijns AC, Moskowitz AJ, et al., for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
8. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336(4):267-276. (Pubitemid 27044630)
9. Fenton MJ, et al. Heart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children. Heart. 2006;92(1):85-89. (Pubitemid 43021864)
10. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331(23):1564-1575. (Pubitemid 24366905)
11. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-1876. (Pubitemid 44596196)
12. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2007;115(5):e172]. Circulation. 2007;115(5):e69-e171. (Pubitemid 46226160)
13. National Heart, Lung, and Blood Institute. Diseases and Conditions Index. Types of cardiomyopathy. http://www.nhlbi.nih.gov/health/dci/Diseases/cm/cm- types.html. Accessed January 16, 2009.
14. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society [published correction appears in Circulation. 2006;113(13):e682-e683]. Circulation. 2005;112(12):1825-1852.
15. Kaski JP, Elliott P. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz. 2007;32(6):446-451. (Pubitemid 47468954)
16. Hypertrophic Cardiomyopathy Association. Genetics and HCM. http://www.4hcm.org/hcm/genetics/3061.html. Accessed February 11, 2009.
17. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713. (Pubitemid 37383745)
18. Hager S, Mahrholdt H, Goldfarb LG, Goebel HH, Sechtem U. Images in cardiovascular medicine. Giant right atrium in the setting of desmin-related restrictive cardiomyopathy. Circulation. 2006;113(4):e53-e55.
19. Eshaghian S, Kaul S, Shah PK. Cardiac amyloidosis: new insights into diagnosis and management. Rev Cardiovasc Med. 2007;8(4):189-199.
20. Cabanes L, Richaud-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 2001;120(6):2047-2050. (Pubitemid 34053471)
21. Maisel AS, Krishnaswamy P, Nowak RM, et al., for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
22. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin. 2001;19(4):557-571. (Pubitemid 33035502)
23. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul study. Am J Med. 2004;116(8):509-516. (Pubitemid 38452641)
24. Blankenberg S, McQueen MJ, Smieja M, et al., for the HOPE Study Investigators. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114(3):201-208. (Pubitemid 44297113)
25. Naylor LH, George K, O'Driscoll G, Green DJ. The athlete's heart: a contemporary appraisal of the 'Morganroth hypothesis.' Sports Med. 2008;38(1):69-90.
26. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115(12):1643-1655.
27. Giese EA, O'Connor FG, Brennan FH, Depenbrock PJ, Oriscello RG. The athletic preparticipation evaluation: cardiovascular assessment. Am Fam Physician. 2007;75(7):1008-1014. (Pubitemid 46556703)
28. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423. (Pubitemid 351653546)
29. The Cardia Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. (Pubitemid 29037695)
30. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/X: Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295-1302. (Pubitemid 30129796)
31. Packer M, Coats AJ, Fowler MB, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. N Engl J Med. 2001;344(22):1651- 1658. (Pubitemid 32479962)
32. Taylor AL, Ziesche S, Yancy C, et al., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction in N Engl J Med. 2005;352(12):1276]. N Engl J Med. 2004;351(20):2049-2057.
33. Feldman D, Menachemi DM, Abraham WT, Wexler RK. Management strategies for stage-D patients with acute heart failure. Clin Cardiol. 2008;31(7):297-301. (Pubitemid 352040151)
34. Shirani J, Maron BJ, Cannon RO III, Shahin S, Roberts WC. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. 1993;72(5):434-440. (Pubitemid 23238428)